Carna Biosciences, Inc. (TYO:4572)
Japan · Delayed Price · Currency is JPY 402.00
-7.00 (-1.71%)
Aug 27, 2026, 1:54 PM JST
Carna Biosciences Cash Flow Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -2,152 | -2,169 | -2,173 | -1,130 | -1,323 | -532 |
Depreciation & Amortization | - | - | 31 | 35 | 33 | 19 |
Loss (Gain) From Sale of Assets | 36 | 24 | 93 | 4 | 44 | 9 |
Other Operating Activities | 51 | 18 | -18 | -35 | -16 | 49 |
Change in Accounts Receivable | -39 | -14 | 704 | -599 | 1,069 | -1,110 |
Change in Inventory | 12 | - | -14 | -21 | -8 | -5 |
Change in Accounts Payable | -24 | -15 | -38 | -44 | -73 | -20 |
Change in Other Net Operating Assets | 37 | -3 | 41 | 113 | -434 | 54 |
Operating Cash Flow | -2,079 | -2,159 | -1,374 | -1,677 | -708 | -1,536 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -13 | -9 | -13 | -11 | -126 | -41 |
Investment in Securities | - | -15 | - | - | - | - |
Other Investing Activities | -7 | -1 | - | - | 1 | - |
Investing Cash Flow | -20 | -25 | -13 | -11 | -125 | -41 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Long-Term Debt Issued | - | 632 | - | - | - | 300 |
Long-Term Debt Repaid | - | -19 | -120 | -151 | -239 | -190 |
Net Debt Issued (Repaid) | 2,075 | 613 | -120 | -151 | -239 | 110 |
Issuance of Common Stock | 54 | - | 694 | 1,343 | 606 | 957 |
Other Financing Activities | -8 | -9 | -7 | -10 | - | -3 |
Financing Cash Flow | 2,121 | 604 | 567 | 1,182 | 367 | 1,064 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Foreign Exchange Rate Adjustments | 16 | -12 | 39 | 16 | 28 | 31 |
Miscellaneous Cash Flow Adjustments | 1 | 1 | 1 | 1 | - | 1 |
Net Cash Flow | 39 | -1,591 | -780 | -489 | -438 | -481 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -2,092 | -2,168 | -1,387 | -1,688 | -834 | -1,577 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -286.97% | -374.44% | -218.08% | -103.88% | -60.17% | -78.19% |
Free Cash Flow Per Share | -108.13 | -113.44 | -77.44 | -100.48 | -61.24 | -124.22 |
Levered Free Cash Flow | -1,407 | -1,411 | -662.38 | -1,290 | -364.5 | -1,451 |
Unlevered Free Cash Flow | -1,354 | -1,379 | -660.5 | -1,287 | -360.75 | -1,449 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 6 | 3 | 2 | 3 | 5 | 4 |
Cash Income Tax Paid | - | -13 | 18 | 33 | 18 | -40 |
Change in Working Capital | -14 | -32 | 693 | -551 | 554 | -1,081 |